Transforming Oncology
Advancing GBM treatment through pioneering research and transformative therapies for improved patient outcomes.
CNS Pharmaceuticals Recently Announced it has Expanded its Pipeline with In-License of Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Company Hosted Webcast July 30th
Our Focus
Our primary focus is on glioma, specifically glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.
Learn More aboutFor Patients
CNS Pharmaceuticals is dedicated to supporting patients and their families throughout their cancer journey. Our 'For Patients' page offers valuable resources, including information about our clinical trials, treatment options, and support networks. Visit our 'For Patients' page to learn more and find the help you need.
Learn More aboutOur Pipeline
Our primary focus is on glioblastoma multiforme, an aggressive and currently incurable form of brain cancer. With a deep understanding of the disease and a commitment to innovation, we aim to change the prognosis for patients suffering from this devastating condition. Discover more about glioblastoma multiforme and our approach to tackling it.
Learn More aboutLatest News
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
Read More of CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdateCNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At The Market Under Nasdaq Rules
Read More of CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At The Market Under Nasdaq RulesCNS Pharmaceuticals Acquires Orphan Drug Designation for Novel Late Stage Abeotaxane TPI 287
Read More of CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel Late Stage Abeotaxane TPI 287Investor Relations
Explore our financial data and market performance. Get a clear picture of our strategic outlook.
Presentations
Access our comprehensive publications and presentations page for information on our research programs.
Email Alerts
Get timely updates on our latest developments. Subscribe to email alerts for new press releases, events, and filings.
Pipeline
Track our ongoing research and development projects. Monitor the progress and future of our drug programs.